<p>MillerKnoll (MLKN) 正在引起新的关注，因为 EIR Healthcare 同意将公司的案例工作和家具直接整合到预制诊所模块中，目标是为像善萨马医院的新加州诊所这样的项目提供更快、经过工厂测试的医疗设施。</p>
<p>查看我们对 MillerKnoll 的最新分析。</p>
<p>EIR Healthcare 的合作恰逢 MillerKnoll 股价动能减弱，过去一个月股价下跌了 16%，过去 90 天下跌了 33.6%。三年总股东回报略微为正，达到 2.2%。</p>
<p>如果这个医疗合同引起了你的注意，值得通过专注于医疗相关机会的筛选器扩大搜索范围，例如 32 只医疗 AI 股票。</p>
<p>尽管 MillerKnoll 的股价在最近几个月大幅下跌，但其交易价格仍大幅低于分析师目标价，并且收入和净收入显示出一定的增长，你不得不问：这种疲软是买入的机会，还是市场已经在定价未来的增长？</p>
<h2>最受欢迎的叙述：54.8% 被低估</h2>
<p>关注 MillerKnoll 的分析师认为每股公允价值为 32 美元，而最后收盘价为 14.46 美元，并基于详细的长期收益和利润率故事来支撑他们的观点。</p>
<blockquote>
<p><em>MillerKnoll 报告部门的重组以更好地与战略目标对齐，可能会改善运营透明度并促进增长，潜在地通过优化资源配置和改善市场聚焦来提升收入和净收益。全球零售部门的扩展，包括新店的开设和产品种类的增长，可能会显著增加未来的收入和收益，因为这提高了品牌知名度并捕获了更大份额的消费者支出。</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>好奇什么样的收入运行率、利润率特征和未来盈利能力需要匹配以支持 32 美元的目标，以及这条路可能需要多长时间。潜在叙述详细说明了具体的增长、盈利能力和估值假设，远远超出了简单的价格目标标题。</p>
<p><strong>结果：公允价值为 32 美元（被低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，关税、北美合同订单疲软以及零售领域早期资产减值显示，收益和利润率预期可能很容易低于这一乐观的剧本。</p>
<p>了解 MillerKnoll 叙述的关键风险。</p>
<h2>另一种观点：市盈率发出截然不同的信号</h2>
<p>虽然分析师和我们的现金流工作指向每股公允价值为 32 美元，但当前的市盈率为 91.5 倍却讲述了一个截然不同的故事。这远高于美国商业服务行业的 21.5 倍、同行平均的 11 倍，甚至高于 39 倍的公允比率，这表明要证明今天的收益倍数，很多事情必须顺利进行。</p>
<p>在过于依赖任何单一方法之前，查看数字在与同行和公允比率基准对比时所暗示的内容是有帮助的，然后问问自己，哪一组假设在 MillerKnoll 的长期表现中更为现实。查看数字对这个价格的看法——在我们的估值分析中了解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33b90cd3-b7be-423d-b79e-c543b64ccc4b/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE3?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33b90cd3-b7be-423d-b79e-c543b64ccc4b/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE3"/></p>
<p>NasdaqGS:MLKN 截至 2026 年 5 月的市盈率</p>
<h2>下一步</h2>
<p>到目前为止，关于价值和风险的信号混杂。如果这让你犹豫不决，请仔细查看完整情况，并权衡两个主要收益和四个重要警告信号。</p>
<h2>寻找更多投资想法？</h2>
<p>如果 MillerKnoll 让你更广泛地思考机会，不要止步于此。使用针对性的股票列表来挖掘你可能错过的想法。</p>
<ul>
<li>通过扫描 51 只高质量被低估股票，寻找潜在的价值机会，这些股票具有稳健的基本面和吸引人的价格。</li>
<li>通过审查 13 只可能提供超过 5% 收益的股息堡垒，专注于收入，强调稳定性。</li>
<li>通过检查 65 只低风险得分的抗风险股票，优先考虑韧性，这些股票在较低风险指标上表现良好。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，性质为一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
<h3><strong>新功能：在一个地方管理所有股票投资组合</strong></h3>
<p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>并且是免费的。</strong></p>
<p>• 连接无限数量的投资组合，并以一种货币查看你的总额</p>
<p>• 通过电子邮件或手机接收新的警告信号或风险的提醒</p>
<p>• 跟踪你股票的公允价值</p>
<p>免费试用演示投资组合</p>

MLKN

<p>MillerKnoll (MLKN) 与 EIR Healthcare 合作，将其产品整合到预制诊所中，旨在加快医疗设施项目的进展。尽管最近股价下跌了 16%，分析师仍将该股票的价值评估为 32 美元，表明其当前价格 14.46 美元被低估。然而，高市盈率和关税、订单疲软等潜在风险引发了对未来收益的担忧。建议投资者在做出决策之前，考虑增长机会和风险</p>

<p>MillerKnoll (MLKN) is drawing fresh attention after EIR Healthcare agreed to integrate the company’s casework and furniture directly into prefabricated clinic modules, targeting faster, factory-tested healthcare facilities for projects such as Good Samaritan Hospital’s new California clinics.</p>
<div class="lb-trans"><p>MillerKnoll (MLKN) 正在引起新的关注，因为 EIR Healthcare 同意将公司的案例工作和家具直接整合到预制诊所模块中，目标是为像善萨马医院的新加州诊所这样的项目提供更快、经过工厂测试的医疗设施。</p>
</div><p>See our latest analysis for MillerKnoll.</p>
<div class="lb-trans"><p>查看我们对 MillerKnoll 的最新分析。</p>
</div><p>The EIR Healthcare partnership comes at a time when momentum in MillerKnoll’s share price has softened, with the stock down 16% over the past month and 33.6% over the past 90 days. The 3 year total shareholder return is slightly positive at 2.2%.</p>
<div class="lb-trans"><p>EIR Healthcare 的合作恰逢 MillerKnoll 股价动能减弱，过去一个月股价下跌了 16%，过去 90 天下跌了 33.6%。三年总股东回报略微为正，达到 2.2%。</p>
</div><p>If this healthcare contract has caught your eye, it could be worth widening your search with a screener focused on healthcare related opportunities such as 32 healthcare AI stocks</p>
<div class="lb-trans"><p>如果这个医疗合同引起了你的注意，值得通过专注于医疗相关机会的筛选器扩大搜索范围，例如 32 只医疗 AI 股票。</p>
</div><p>With MillerKnoll shares down sharply in recent months yet trading at a steep discount to analyst targets and some growth showing in revenue and net income, you have to ask: is this weakness a chance to buy, or is the market already pricing in future growth?</p>
<div class="lb-trans"><p>尽管 MillerKnoll 的股价在最近几个月大幅下跌，但其交易价格仍大幅低于分析师目标价，并且收入和净收入显示出一定的增长，你不得不问：这种疲软是买入的机会，还是市场已经在定价未来的增长？</p>
</div><h2>Most Popular Narrative: 54.8% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：54.8% 被低估</h2>
</div><p>Analysts who follow MillerKnoll see a fair value of $32 per share, compared with the last close at $14.46, and anchor their view on a detailed long term earnings and margin story.</p>
<div class="lb-trans"><p>关注 MillerKnoll 的分析师认为每股公允价值为 32 美元，而最后收盘价为 14.46 美元，并基于详细的长期收益和利润率故事来支撑他们的观点。</p>
</div><blockquote>
<p><em>The restructuring of MillerKnoll's reporting segments to better align with strategic goals could improve operational clarity and facilitate growth, potentially boosting revenue and net earnings by optimizing resource allocation and improving market focus. Expansion in the Global Retail segment, including the opening of new stores and the growth of product assortment, could significantly increase future revenue and earnings as it raises brand visibility and captures a larger share of consumer spending.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>MillerKnoll 报告部门的重组以更好地与战略目标对齐，可能会改善运营透明度并促进增长，潜在地通过优化资源配置和改善市场聚焦来提升收入和净收益。全球零售部门的扩展，包括新店的开设和产品种类的增长，可能会显著增加未来的收入和收益，因为这提高了品牌知名度并捕获了更大份额的消费者支出。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>Curious what kind of revenue run rate, margin profile, and future earnings power have to line up to support that $32 mark, and how long that road might be. The underlying narrative spells out specific growth, profitability, and valuation assumptions that go well beyond a simple price target headline.</p>
<div class="lb-trans"><p>好奇什么样的收入运行率、利润率特征和未来盈利能力需要匹配以支持 32 美元的目标，以及这条路可能需要多长时间。潜在叙述详细说明了具体的增长、盈利能力和估值假设，远远超出了简单的价格目标标题。</p>
</div><p><strong>Result: Fair Value of $32 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 32 美元（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, tariffs, weaker North America Contract orders, and earlier asset impairments in Retail show that earnings and margin expectations could easily fall short of this upbeat script.</p>
<div class="lb-trans"><p>然而，关税、北美合同订单疲软以及零售领域早期资产减值显示，收益和利润率预期可能很容易低于这一乐观的剧本。</p>
</div><p>Find out about the key risks to this MillerKnoll narrative.</p>
<div class="lb-trans"><p>了解 MillerKnoll 叙述的关键风险。</p>
</div><h2>Another View: P/E Ratios Flash A Very Different Signal</h2>
<div class="lb-trans"><h2>另一种观点：市盈率发出截然不同的信号</h2>
</div><p>While analysts and our cash flow work point to a fair value of $32 per share, the current P/E of 91.5x tells a very different story. It is far above the US Commercial Services industry at 21.5x, the peer average at 11x, and even the 39x fair ratio, which suggests a lot has to go right to justify today’s earnings multiple.</p>
<div class="lb-trans"><p>虽然分析师和我们的现金流工作指向每股公允价值为 32 美元，但当前的市盈率为 91.5 倍却讲述了一个截然不同的故事。这远高于美国商业服务行业的 21.5 倍、同行平均的 11 倍，甚至高于 39 倍的公允比率，这表明要证明今天的收益倍数，很多事情必须顺利进行。</p>
</div><p>Before you lean too heavily on any single approach, it can help to see what the numbers imply when lined up against peers and that fair ratio benchmark, and then ask yourself which set of assumptions feels more realistic for MillerKnoll over time.See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>在过于依赖任何单一方法之前，查看数字在与同行和公允比率基准对比时所暗示的内容是有帮助的，然后问问自己，哪一组假设在 MillerKnoll 的长期表现中更为现实。查看数字对这个价格的看法——在我们的估值分析中了解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/33b90cd3-b7be-423d-b79e-c543b64ccc4b/chart/pe-multiple-vs-industry/query-ZGF0ZT0yMDI2LTA1LTE3" alt="" original-src="https://images.simplywall.st/company/33b90cd3-b7be-423d-b79e-c543b64ccc4b/chart/pe-multiple-vs-industry?date=2026-05-17"/></p>
<p>NasdaqGS:MLKN P/E Ratio as at May 2026</p>
<div class="lb-trans"><p>NasdaqGS:MLKN 截至 2026 年 5 月的市盈率</p>
</div><h2>Next Steps</h2>
<div class="lb-trans"><h2>下一步</h2>
</div><p>Mixed signals on value and risk so far. If this has you on the fence, take a closer look at the full picture and weigh the 2 key rewards and 4 important warning signs.</p>
<div class="lb-trans"><p>到目前为止，关于价值和风险的信号混杂。如果这让你犹豫不决，请仔细查看完整情况，并权衡两个主要收益和四个重要警告信号。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>If MillerKnoll has you thinking more broadly about opportunities, do not stop here. Use targeted stock lists to surface ideas you might otherwise miss.</p>
<div class="lb-trans"><p>如果 MillerKnoll 让你更广泛地思考机会，不要止步于此。使用针对性的股票列表来挖掘你可能错过的想法。</p>
</div><ul>
<li>Hunt for potential value opportunities by scanning 51 high quality undervalued stocks that pair solid fundamentals with attractive prices.</li>
<li>Focus on income by reviewing 13 dividend fortresses that may offer yields above 5% with an emphasis on stability.</li>
<li>Prioritize resilience by checking 65 resilient stocks with low risk scores that score well on lower risk metrics.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过扫描 51 只高质量被低估股票，寻找潜在的价值机会，这些股票具有稳健的基本面和吸引人的价格。</li>
<li>通过审查 13 只可能提供超过 5% 收益的股息堡垒，专注于收入，强调稳定性。</li>
<li>通过检查 65 只低风险得分的抗风险股票，优先考虑韧性，这些股票在较低风险指标上表现良好。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，性质为一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不旨在提供财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑你的目标或财务状况。我们旨在为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div><h3><strong>New:</strong> Manage All Your Stock Portfolios in One Place</h3>
<div class="lb-trans"><h3><strong>新功能：在一个地方管理所有股票投资组合</strong></h3>
</div><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p>
<div class="lb-trans"><p>我们为股票投资者创建了 <strong>终极投资组合伴侣</strong>，<strong>并且是免费的。</strong></p>
</div><p>• Connect an unlimited number of Portfolios and see your total in one currency</p>
<div class="lb-trans"><p>• 连接无限数量的投资组合，并以一种货币查看你的总额</p>
</div><p>• Be alerted to new Warning Signs or Risks via email or mobile</p>
<div class="lb-trans"><p>• 通过电子邮件或手机接收新的警告信号或风险的提醒</p>
</div><p>• Track the Fair Value of your stocks</p>
<div class="lb-trans"><p>• 跟踪你股票的公允价值</p>
</div><p>Try a Demo Portfolio for Free</p>
<div class="lb-trans"><p>免费试用演示投资组合</p>
</div>

在与 EIR Healthcare 达成预制诊所领域的新合作后，评估 MillerKnoll (MLKN) 的估值